GetTopicDetailResponse(id=bda71331e52, topicName=Olumiant, introduction=Olumiant, content=null, image=null, comments=5, allHits=1213, url=https://h5.medsci.cn/topic?id=13317, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93680, tagList=[TagDto(tagId=93680, tagName=Olumiant)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1981832, encodeId=e3f3198183283, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK 抑制劑 Olumiant 在 RA 中的新長期陽性數(shù)據(jù), objectType=article, longId=220347, objectId=48aa22034ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48aa22034ed7, replyNumber=0, likeNumber=114, createdTime=2022-07-30, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48aa22034ed7, moduleTitle=JAK 抑制劑 Olumiant 在 RA 中的新長期陽性數(shù)據(jù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=48aa22034ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981833, encodeId=9b3819818333c, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=禮來（Lilly）的Olumiant在狼瘡、特應(yīng)性皮炎適應(yīng)癥中遭遇挫折, objectType=article, longId=295103, objectId=2e0c295103eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0c295103eb, replyNumber=0, likeNumber=99, createdTime=2022-09-17, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0c295103eb, moduleTitle=禮來（Lilly）的Olumiant在狼瘡、特應(yīng)性皮炎適應(yīng)癥中遭遇挫折, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2e0c295103eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981831, encodeId=473a1981831c4, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK抑制劑Olumiant和抗血管生成素-2單抗LY3127804將用于新冠病毒COVID-19患者臨床試驗, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=95, createdTime=2020-04-26, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制劑Olumiant和抗血管生成素-2單抗LY3127804將用于新冠病毒COVID-19患者臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981830, encodeId=bcd81981830aa, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=JAK抑制劑Olumiant聯(lián)合治療特應(yīng)性皮炎的III期試驗達(dá)到主要終點, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=85, createdTime=2020-05-21, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制劑Olumiant聯(lián)合治療特應(yīng)性皮炎的III期試驗達(dá)到主要終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981829, encodeId=7c09198182909, content=<a href='/topic/show?id=bda71331e52' target=_blank style='color:#2F92EE;'>#Olumiant#</a>, objectTitle=禮來JAK抑制劑Olumiant治療系統(tǒng)性紅斑狼瘡的2期臨床試驗獲得成功, objectType=article, longId=145138, objectId=96a9145138b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96a9145138b2, replyNumber=0, likeNumber=95, createdTime=2018-11-01, rootId=0, userName=tongyongming, userId=76d3356, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96a9145138b2, moduleTitle=禮來JAK抑制劑Olumiant治療系統(tǒng)性紅斑狼瘡的2期臨床試驗獲得成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=96a9145138b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
